Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_2

33%

Ph phase_1

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(1)

Other(1)

Detailed Status

unknown1

Completed1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 31 (33.3%)

Trials by Status

unknown133%

completed133%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_3

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

NCT04600921

completedphase_2

Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction

NCT05388825

unknownphase_1

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

NCT04178070

Clinical Trials (3)

Showing 3 of 3 trials

NCT04600921Phase 3

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

Terminated

NCT05388825Phase 2

Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction

Completed

NCT04178070Phase 1

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Unknown

All 3 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 3